Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Alterity Therapeutics LimitedNASDAQ: ATHE

Net Income · Q2 FY2026 · quarter ended Dec 2025

Net income grows 31.6% year over year

Q2 FY2026 net income of A$9.44M (cash outflow) rose 31.6% year over year. Over 3 fiscal years it compounded at -1.8% a year.

Context

  • Net income amounted to 223.4% of revenue in FY2025, down 252.4 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -A$6.95M (-42.8%) for the fiscal year ending Jun 2026, a slowdown from the -36.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$9.44M— QoQ
Last fiscal yearJun 2025
-A$12.15M-36.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.6%——
1 year-36.5%-42.8%-6.3 pp
3-year CAGR-1.8%-21.2%-19.4 pp
5-year CAGR-19.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

AUD · from the cash flow

Latest · FY2025
(12.15M) AUD
Year-over-year change
+36.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -36.5% is the lowest of 4, against a peer median of +25.1%.
  • Net income amounts to 223.4% of revenue for ATHE, versus a peer median of 245.1%.
ATHE Competitors
Net Income for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$40.92M USD+40.8%+944.4%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$24.25M USD+23.1%+12.4%—
ATHEAlterity Therapeutics LimitedFY2025A$12.15M AUD-36.5%-1.8%223.4%
DYAIDyadic International, Inc.LTM Mar 2026$7.29M USD+25.1%-8.9%245.1%
Peer median (excluding ATHE) —+25.1%+12.4%245.1%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Depreciation & Amortization75.37K54.21K102.26K147.53K139.72K
Deferred Income Tax2.33M(1.06M)2.99M00
Stock-Based Compensation1.88M1.51M966.57K881.95K979.92K
Change in Working Capital(4.22M)(447.68K)(3.94M)5.75M(613.68K)
Accounts Receivables(4.22M)(447.68K)(3.94M)4.62M104.07K
Inventory191.13K(2.21M)2.45M00
Accounts Payables432.91K2.6M(1.56M)1.1M0
Other Working Capital(624.03K)(393.29K)(889.52K)23.05K(717.75K)
Other Non-Cash Items(2.1M)455.57K(6.35M)(261.15K)190.62K
Operating Cash Flow(17.33M)(12.34M)(20.04M)(12.61M)(11.45M)
Capital Expenditures(10.47K)(89.15K)(7.31K)(5.72K)3
Acquisitions (Net)00000
Purchases of Investments0000(7.5M)
Sales of Investments00000
Other Investing Activities00(29.15K)00
Investing Cash Flow(10.47K)(89.15K)(36.46K)(5.72K)(7.5M)
Debt Repayment(58.29K)(34.51K)(59.92K)(10.37K)(127.1K)
Common Stock Issued39.24M17.18M316.68K10.14M42.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.49M)(836.97K)(132.41K)(918.02K)(2.77M)
Financing Cash Flow36.69M16.3M124.34K9.22M39.67M
Effect of Forex Changes(426.78K)2.81M914.94K260.36K(198.38K)
Net Change in Cash18.92M6.69M(19.03M)(3.13M)20.52M
Free Cash Flow(17.34M)(12.43M)(20.04M)(12.61M)(11.45M)

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.